MedTrace Logo

Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis

NCT04855617 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 122

Last updated 2023-06-15

No results posted yet for this study

Summary

This study is designed to determine whether symptom burden differs by time to infusion.

Conditions

Interventions

DRUG

Ocrelizumab

Administer Ocrelizumab under the close supervision of an experienced healthcare professional with access to appropriate medical support to manage severe reactions such as serious infusion reactions. * Initial dose: 300 mg intravenous infusion, followed two weeks later by a second 300 mg intravenous infusion. * Subsequent doses: single 600 mg intravenous infusion every 6 months. * Observe the patient for at least one hour after the completion of the infusion

Sponsors & Collaborators

Principal Investigators

  • Ilya Kister, MD · NYU Langone Health

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-26
Primary Completion
2022-10-01
Completion
2022-10-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04855617 on ClinicalTrials.gov